NEW DRUG-INTERACTIONS WITH ZIDOVUDINE

Polypharmacy is commonly encountered in human immunodeficiency virus ( HIV)-positive patients, and the risk and frequency of drug-drug intera ctions are significant in this patient population. Most HIV-positive p atients receive the antiretroviral drug zidovudine (3'-azido-3'-deoxyt hymidine, ZDV), the first drug to be approved for the treatment of HIV . Many drug interactions with ZDV have already been reported. As HIV p harmacotherapy becomes more complex, the potential for drug-drug inter actions is likely to increase significantly.